pSivida
edit

pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, a drug is released on a controlled and level basis for months or years. The Company has two core technology systems, Durasert and BioSilicon. pSivida Corp. has one product candidate for chronic eye disease that has been given Priority Review by the United States Food and Drug Administration (FDA). It has a collaboration with Pfizer, Inc. (Pfizer) to develop additional ophthalmic products. Iluvien, the product candidiate with Priority Review, is designed to provide sustained release treatment for Diabetic Macula Edema (DME). Iluvien is licensed to Alimera Sciences, Inc (Alimera), which is completing fully-recruited Phase III clinical trials.

Recent Milestones
edit

pSivida received $40M in Venture Round funding. (7/18/12)

Posted 7/18/12 at 7:45pm via masshightech.com
pSivida — reports positive results from a 36-month trial of its Iluvien treatment for diabetic macular edema (DME), which affects some 1 million Americans (2/3/11)

Posted 2/7/11 at 4:35am via masshightech.com
pSivida — breathing new life into off-patent drugs by using them with its miniaturized drug-delivery products, which deliver lower, time-released doses of therapies for longer periods (2/3/11)

Posted 2/7/11 at 5:30am via masshightech.com
pSivida — pSivida raising $11M financing (1/19/11)

Posted 1/20/11 at 6:58pm via masshightech.com
Went public with stock symbol NASDAQ:PSDV.

Posted 1/20/11 at 6:52pm
pSivida added Paul Ashton as President and CEO.

Posted 1/20/11 at 6:52pm
pSivida added Len Ross as Vice President, Finance.

Posted 12/2/12 at 9:03pm
pSivida added Marty Nazzaro as Vice President of Operations.

Posted 12/2/12 at 9:03pm